Dr. Brian S. Henick, a medical oncologist at Columbia University Irving Medical Center and director of the phase 1 program ...

The 2026 IASLC Targeted Therapies in Lung Cancer meeting brought together leading oncologists, surgeons, and patient ...

Pegvisomant, developed by professor John Kopchick in 1987, shows potential to make treatment-resistant lung cancer cells more ...

GSK plc GSK announced that Japan’s Ministry of Health, Labour and Welfare has granted Orphan Drug Designation (ODD) to ...

In recent decades, lung cancer treatment has been transformed—new surgeries, new radiation techniques, and dramatically ...

Immunotherapy is a cancer treatment that harnesses the body’s immune system to fight cancer. It helps the immune system recognize and attack cancer cells, which can sometimes be hidden from the body’s ...

Presentations showcase progress in BioNTech's late-stage lung cancer programs, reinforcing the potential of the Company's differentiated portfolio spanning immunomodulators, antibody-drug conjugates, ...

Targeted therapies are cancer medications that work more selectively than standard chemotherapy medications. They do this by targeting specific molecules or genetic changes in cancer cells in order to ...

Thanks to recent therapy advances, the lung cancer mortality rate has declined and survival rates have improved. Many factors influence the likelihood of a lung cancer cure or long-term survival, ...

The likelihood that a person with early-stage non-small cell lung cancer will receive curative treatment still varies ...

“Lung cancer, though common and serious, still has many misconceptions,” says Ian Bostock, MD, a thoracic surgeon at Miami Cancer Institute in Florida. “Clearing these myths helps patients and ...

The American Lung Association will hold its 11th annual LUNG FORCE Advocacy Day on Wednesday, March 25. More than 50 people from across the country whose lives have been impacted by lung cancer will ...